Acuson's long-suffering stock price got a big boost this monthafter an analyst at Morgan Stanley raised his rating of the stockfrom "neutral" to "outperform."The Mountain View, CA, ultrasound vendor's stock leaped 31%the week of Sept.
Acuson's long-suffering stock price got a big boost this monthafter an analyst at Morgan Stanley raised his rating of the stockfrom "neutral" to "outperform."
The Mountain View, CA, ultrasound vendor's stock leaped 31%the week of Sept. 9, from $13.63 on Sept. 8, the day before therating was issued, to $17.88 at the end of the week. It was tradingat around $17.50 last week.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.
2 Commerce Drive
Cranbury, NJ 08512